PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations

Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 or its ligand (PD-L1) have improved outcomes in non-small cell lung cancer (NSCLC). High tumor PD-L1 expression, detected by immunohistochemistry (IHC) typically on formalin-fixed paraffin-embedded (FFPE) histological specimens, is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansour, Mohammed S. I., Malmros, Karina, Mager, Ulrich, Ericson Lindquist, Kajsa, Hejny, Kim, Holmgren, Benjamin, Seidal, Tomas, Dejmek, Annika, Dobra, Katalin, Planck, Maria, Brunnström, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101150/
https://www.ncbi.nlm.nih.gov/pubmed/35562908
http://dx.doi.org/10.3390/ijms23094517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101150/
https://www.ncbi.nlm.nih.gov/pubmed/35562908
http://dx.doi.org/10.3390/ijms23094517

Ejemplares similares